Revaccination of children with acute lymphoblastic leukemia following completion of chemotherapyArticle Published on 2023-06-012023-06-02 Journal: Pediatric blood & cancer [Category] 두창, 수두, 홍역, [키워드] Humoral immunity leukemia pediatrics vaccination. [DOI] 10.1002/pbc.30321 PMC 바로가기
Revaccination of children with acute lymphoblastic leukemia following completion of chemotherapyArticle Published on 2023-06-012023-06-02 Journal: Pediatric blood & cancer [Category] 두창, 홍역, [키워드] Humoral immunity leukemia pediatrics vaccination. [DOI] 10.1002/pbc.30321 PMC 바로가기
Novel coronavirus infection (COVID-19) in a 12-year-old boy with acute lymphoblastic leukemiaCase Reports Published on 2022-12-012023-07-11 Journal: Journal of cancer research and therapeutics [Category] COVID19(2023년), [키워드] Chemotherapy COVID-19 leukemia pediatric. [DOI] 10.4103/jcrt.JCRT_653_20 PMC 바로가기 [Article Type] Case Reports
Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs HospitalsArticle Published on 2022-10-032022-11-15 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI adjusted odds ratio Affair age antiviral therapy association benefit black blood oxygen level booster booster vaccination Breakthrough infection Characteristics Chemotherapy chronic condition Chronic kidney disease collected Comorbidities conditions COVID-19 death defined Dementia demographic Department development Dexamethasone diagnostic disease dose effort end-organ Factor finding heart failure Hispanic Hospitalization hospitals identify immunocompromised status Immunosuppressive medication increase in increased risk Infection laboratory-confirmed SARS-CoV-2 infection less leukemia leukocyte logistic regression models lymphoma male mechanical ventilation men Older outcome Patient positive preexposure prophylaxis proportion receipt reduced retrospective cohort retrospective cohort study risk risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination severe COVID-19 severe COVID-19 disease severe disease Severe infection supplemental oxygen treated vaccination Vaccine variables veteran veterans white [DOI] 10.1001/jamanetworkopen.2022.40037 PMC 바로가기
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignanciesArticle Published on 2022-10-012022-11-15 Journal: American journal of hematology [Category] COVID19(2023년), SARS, 진단, [키워드] active treatment B-cell malignancies B-cell malignancy BNT162b2 BNT162b2 vaccine booster booster dose Comparisons Control COVID19 disease dose elicited ENhance enrolled evaluated healthy controls high-risk population Humoral response immune response leukemia median NAb nAb response NAb titer NAbs NHL Patient patient group patients Prognostic factor proportion Protective response SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccination significantly significantly lower Treatment vaccination [DOI] 10.1002/ajh.26669 PMC 바로가기
SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemiaArticle Published on 2022-10-012022-11-15 Journal: Haematologica [Category] COVID19(2023년), SARS, 진단, [키워드] cellular response COVID-19 vaccination leukemia Patient [DOI] 10.3324/haematol.2022.280982 PMC 바로가기
Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary?그리스의 면역 저하 성인에서 SARS-CoV-2 BNT162b2 백신 3차 접종 후 항체 역가: 4차 접종이 필요한가요?Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age anti-S Anti-spike antibody Antibody titers Autoimmune autoimmune diabete autoimmune diabetes Autoimmune disease average baseline BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BNT162b2 vaccine change correlated COVID-19 Decline decrease diabetes dose Effectiveness fold Fold change Fold changes Greece humoral Humoral response IgG antibody titer IgG antibody titers IgG GMC Immunocompromised immunocompromised adult immunocompromised adults immunocompromised individual immunocompromised individuals immunogenicity Inflammatory inflammatory disease leukemia lymphoma mRNA of BNT162b2 Omicron variant Omicron variants postvaccination real-world data SARS-CoV-2 serum sample serum samples Sex significantly the SARS-CoV-2 the vaccine third dose. vaccination Vaccine vaccine dose vulnerable population [DOI] 10.1002/jmv.27954 PMC 바로가기 [Article Type] Article
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccinationArticle Published on 2022-09-132022-11-15 Journal: Immunity [Category] COVID19(2023년), SARS, 진단, [키워드] B cells CD4 CD45RA CD8 Cell-mediated immunity Characteristics continuum COVID-19 elicited form functional highlighting Humoral immunity Immunocompromised patient Immunocompromised patients immunodeficiency Impaired in healthy individual individual lack leukemia mRNA vaccination mRNA vaccine mRNA vaccine. Patient patients polyclonal response responses RNA-sequencing robust SARS-CoV-2 SARS-CoV-2-specific T cell single-cell profile solid-organ transplant spike-specific T cell syndrome T cell T cell response T cells vaccination X-linked agammaglobulinemia XLA [DOI] 10.1016/j.immuni.2022.07.005 PMC 바로가기
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies혈액암이 있는 성인 환자의 SARS-CoV-2 백신 1차 및 2차 접종에 대한 면역 반응의 체계적인 검토 및 메타 분석Review Published on 2022-09-012022-09-11 Journal: International immunopharmacology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% confidence interval 95%CI affected affecting anti-CD20 therapy antibody Antibody detection Antibody Response article booster dose booster doses calculated Cancer patients chronic lymphocytic leukemia CLL Complete conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines develop Diagnosis disease doses evaluate first dose Google Google Scholar healthy subject healthy subjects Hematological malignancies Hematological malignancy higher risk highlight highlighting immune response Immunity immunization Immunocompromised immunogenicity immunosuppressive IMPROVE kinase inhibitors less leukemia lowest Lymphocytic leukemia lymphoma malignancy measure Meta-analysis mRNA mRNA-1273 Myeloma Patient Primary outcome response rate SARS-CoV-2 SARS-CoV-2 vaccine second dose secondary outcome Secondary outcomes seropositive Seropositivity severe coronavirus disease solid tumor solid tumors status subgroup subtype systematic review systematic review. the disease the vaccine tumors tyrosine tyrosine kinase inhibitor tyrosine kinase inhibitors Vaccine vaccine dose vaccine's immunogenicity Web of Science [DOI] 10.1016/j.intimp.2022.109046 PMC 바로가기 [Article Type] Review
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLLArticle Published on 2022-08-262022-11-15 Journal: Journal of Hematology & Oncology [Category] SARS, 진단, [키워드] 95%CI Admission advanced age affected age albumin Analysis anticoagulation therapy bleeding C-reactive protein CLL Complication conducted COVID-19 COVID-19 diagnosis D-dimer Data collection death deficiency defined development dose administration ENhance European event high risk Hospitalization Hospitalized ICU immune increased risk initiative leukemia LMWH Most patient multivariate model nasal Occurrence outcomes oxygen oxygen supplementation Patient peak D-dimer pharyngeal polymerase chain presence of comorbidities Prognostic factor prophylactic dose Protective receiving recommendation reported Retrospective multicenter study risk RT-PCR SARS-CoV-2 severe COVID-19 severity STROBE susceptible swabs the disease Thromboembolic event Thromboprophylaxis thrombosis thrombosis. Thrombotic events Treatment treatment for COVID-19 were used [DOI] 10.1186/s13045-022-01333-0 PMC 바로가기